Mounjaro KwikPen contains tirzepatide, a once-weekly injectable medicine. It is mainly used for type 2 diabetes and, depending on the country/approved indication, for weight management. It works on both GIP and GLP-1 receptors, helping lower blood sugar and reduce appetite.
Typical starting dose: 2.5 mg once weekly for 4 weeks, then 5 mg once weekly; doses can be increased gradually under medical supervision.
Common side effects: nausea, diarrhea, reduced appetite, vomiting, constipation, indigestion and abdominal pain.
Do not use if you or a family member has had medullary thyroid carcinoma (MTC) or if you have MEN2.
The KwikPen is for one patient only and must not be shared, even if the needle is changed.
If you tell me your Mounjaro strength (2.5/5/7.5/10/12.5/15 mg), I can explain how to use the KwikPen, how many doses it contains, and how to store it.
